11:24 AM EDT, 06/07/2024 (MT Newswires) -- Moderna ( MRNA ) said Friday it has submitted an application to the US Food and Drug Administration for reviewing its Spikevax 2024-2025 formula, a vaccine targeting the SARS-CoV-2 variant JN.1.

The application is based on the regulator's recommendation that COVID-19 vaccines should be updated to a monovalent JN.1 composition for the 2024-2025 season, the drugmaker said.

Spikevax 2024-2025 formula's doses will be ready to ship as early as August, pending regulatory approvals, the company said.

Shares of Moderna ( MRNA ) fell 1.6% in recent trading.

Price: 152.17, Change: -2.52, Percent Change: -1.63